Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
September 24, 2024 07:30 ET
|
Cytokinetics, Incorporated
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 4th, 2024 SOUTH SAN...
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
September 19, 2024 16:00 ET
|
Cytokinetics, Incorporated
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE...
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
September 09, 2024 07:30 ET
|
Cytokinetics, Incorporated
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics,...
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
September 05, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two presentations at the 2024 American College of Clinical Pharmacology...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 30, 2024 it granted stock options to purchase an aggregate of...
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
September 01, 2024 04:27 ET
|
Cytokinetics, Incorporated
Data from Integrated Safety Analysis Across Three Clinical TrialsReinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal of Standard of Care...
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
September 01, 2024 03:51 ET
|
Cytokinetics, Incorporated
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography,Symptom Relief and Improvement in Biomarkers...
Cytokinetics to Participate in September Investor Conferences
August 29, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor...
Cytokinetics Reports Second Quarter 2024 Financial Results
August 08, 2024 16:00 ET
|
Cytokinetics, Incorporated
Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten;Company Has Initiated Rolling NDA Submission FDA Cleared Protocol Amendment for FOREST-HCM Reducing...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 01, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 31, 2024 it granted stock options to purchase an aggregate of...